Construction of a Hypoxia-related lncRNA Prognostic Model for Bladder Urothelial Carcinoma Based on TCGA Database
1. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510030, China
2. Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, China
| Abstract: | Objective: To investigate the relationship between hypoxia regulation-related lncRNA and the prognosis and treatment of patients with bladder urothelial carcinoma, so as to provide new ideas for clinical medicine. Methods: Clinical and genomic data were obtained from The Cancer Genome Atlas (TCGA) database, and hypoxia-related genes were obtained from the (GSEA) database. Prognostic models were constructed by co-expression analysis and Cox regression analysis. The roles of hypoxia-related lncRNAs in the tumor immune environment were revealed by GO, KEGG and tumor mutational burden (TMB) analysis. Results: A prognostic model containing 6 hypoxia-related lncRNAs was constructed. We found that low-risk patients had better overall survival (OS) and progression-free survival (PFS). ROC, independent predictive analysis, C-index, and nomogram indicated that hypoxia-related lncRNA models could independently predict patient outcomes. TMB analysis suggested that the biological function of hypoxia-related lncRNA was related to tumor immunity, and patients with low risk and high TMB had better prognosis. Conclusion: We constructed a hypoxia-related lncRNA prognostic model for patients with bladder urothelial carcinoma, and patients with low risk and high TMB had longer overall survival (OS). |
| Keywords: | Hypoxia; Urothelial Carcinoma of the Bladder; Long Noncoding RNA; Prognostic Risk Models; Tumor Mutational Burden |
| DOI: | 10.57237/j.wjcm.2023.03.003 |
View:
Downloads:
Received: 4 July 2023
Accepted: 31 August 2023
Published Online: 8 September 2023
References
| [1] | Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394-424. |
| [2] | Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020; 38 (8): 1895-904. |
| [3] | Xu M, Mu J, Wang J, Zhou Q, Wang J. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. Front Oncol. 2022; 12: 961213. |
| [4] | Petrova V, Annicchiarico-Petruzzelli M, Melino G, Amelio I. The hypoxic tumour microenvironment. Oncogenesis. 2018; 7 (1): 10. |
| [5] | Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019; 18 (1): 157. |
| [6] | Lu M, Ge Q, Wang G, Luo Y, Wang X, Jiang W, et al. CIRBP is a novel oncogene in human bladder cancer inducing expression of HIF-1α. Cell Death Dis. 2018; 9 (10): 1046. |
| [7] | Xue M, Chen W, Xiang A, Wang R, Chen H, Pan J, et al. Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1. Mol Cancer. 2017; 16 (1): 143. |
| [8] | Terry S, Buart S, Chouaib S. Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity. Front Immunol. 2017; 8: 1625. |
| [9] | Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10 (3): 155-9. |
| [10] | Meryet-Figuière M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L, et al. An overview of long non-coding RNAs in ovarian cancers. Oncotarget. 2016; 7 (28): 44719-34. |
| [11] | Chen S, Shen X. Long noncoding RNAs: functions and mechanisms in colon cancer. Mol Cancer. 2020; 19 (1): 167. |
| [12] | Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv L, et al. Noncoding RNAs in gastric cancer: implications for drug resistance. Mol Cancer. 2020; 19 (1): 62. |
| [13] | Li Z, Qin X, Bian W, Li Y, Shan B, Yao Z, et al. Exosomal lncRNA ZFAS1 regulates esophageal squamous cell carcinoma cell proliferation, invasion, migration and apoptosis via microRNA-124/STAT3 axis. J Exp Clin Cancer Res. 2019; 38 (1): 477. |
| [14] | Wang F, Lin H, Su Q, Li C. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma. World J Surg Oncol. 2022; 20 (1): 275. |
| [15] | Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28 (11): 1747-56. |
| [16] | Mo X, Hu D, Li Y, Nai A, Ma F, Bashir S, et al. A novel pyroptosis-related prognostic lncRNAs signature, tumor immune microenvironment and the associated regulation axes in bladder cancer. Front Genet. 2022; 13: 936305. |
| [17] | Zhou M, Zhang Z, Bao S, Hou P, Yan C, Su J, et al. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform. 2021; 22 (3). |
| [18] | Zheng Z, Lai C, Li W, Zhang C, Ma K, Yao Y. Identification of a Novel Glycolysis-Related LncRNA Signature for Predicting Overall Survival in Patients With Bladder Cancer. Front Genet. 2021; 12: 720421. |
| [19] | Tan W, Yuan Y, Huang H, Ma J, Li Y, Gou Y, et al. Comprehensive analysis of autophagy related long non-coding RNAs in prognosis, immunity, and treatment of muscular invasive bladder cancer. Sci Rep. 2022; 12 (1): 11242. |
| [20] | Tang D, Li Y, Tang Y, Zheng H, Luo W, Li Y, et al. Recognition of Glycometabolism-Associated lncRNAs as Prognosis Markers for Bladder Cancer by an Innovative Prediction Model. Front Genet. 2022; 13: 918705. |
| [21] | Zhou XY, Dai HY, Zhang H, Zhu JL, Hu H. Ferroptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Carcinoma. Biomed Res Int. 2022; 2022: 2056913. |
| [22] | Lu J, Xu F, Lu H. LncRNA PVT1 regulates ferroptosis through miR-214-mediated TFR1 and p53. Life Sci. 2020; 260: 118305. |
| [23] | Li Z, Wang D, Yin H. A seven immune-related lncRNA signature predicts the survival of patients with colon adenocarcinoma. Am J Transl Res. 2020; 12 (11): 7060-78. |
| [24] | Dai T, Li J, Ye L, Yu H, Deng M, Liu W, et al. Prognostic Role and Potential Mechanisms of N6-methyladenosine-related Long Noncoding RNAs in Hepatocellular Carcinoma. J Clin Transl Hepatol. 2022; 10 (2): 308-20. |
| [25] | Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2021; 39 (2): 154-73. |
| [26] | Fusco MJ, West HJ, Walko CM. Tumor Mutation Burden and Cancer Treatment. JAMA Oncol. 2021; 7 (2): 316. |
| [27] | McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021; 32 (5): 661-72. |
| [28] | Valero C, Lee M, Hoen D, Wang J, Nadeem Z, Patel N, et al. The association between tumor mutational burden and prognosis is dependent on treatment context. Nat Genet. 2021; 53 (1): 11-5. |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us